Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects

Arzt, Lisa; Bokanovic, Danijela; Schrautzer, Christoph; Laipold, Karin; Möbs, Christian; Pfützner, Wolfgang; Herzog, Sereina A.; Vollmann, Jutta; Reider, Norbert; Bohle, Barbara; Aberer, Werner; Sturm, Gunter J.

doi:10.1111/all.13368

Cited by 32 publications

(39 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30The recent study by Arzt et al demonstrated higher specific/total IgE ratios in patients with clinically relevant VV allergy compared to participants with asymptomatic sensitization to VV and rVes v 5 21. Our current data likewise indicate low specific/total IgE ratios for BV and VV as well as the respective marker allergens in individuals without a history of sting-induced anaphylaxis (Figure 2).…”

supporting

confidence: 73%

“…[15][16][17][18][19] This hypothesis has been critically questioned by some authors 20 and stands in some contrast to the observation that most subjects with hitherto asymptomatic sensitization to nonglycosylated recombinant Hymenoptera venom allergens tolerate deliberate sting challenges with the respective insect. 6,21 A recent study based on a cross-sectional population survey likewise suggests that sensitization to Hymenoptera venom marker allergens is common in the general population, whereas its clinical relevance might be low. 22 Other than in the study by Mos-…”

Section: Predisposing Factors For Marker Allergen-specific Sensitizmentioning

confidence: 99%

“…In accordance with previous studies on the natural course of sensitization to Hymenoptera venoms, our data suggest that sensitization to VV marker allergens peaks shortly after the sting, subsequently wanes, and may fall below the limits of detection within a couple of years. 5,7,21,26,27…”

Section: Recent Hymenoptera Stingsmentioning

confidence: 99%

See 2 more Smart Citations

Sensitization to Hymenoptera venom marker allergens: Prevalence, predisposing factors, and clinical implications

Stoevesandt

Hosp

Kerstan

et al. 2018

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

supporting

confidence: 73%

Section: Predisposing Factors For Marker Allergen-specific Sensitizmentioning

confidence: 99%

See 1 more Smart Citation

Sensitization to Hymenoptera venom marker allergens: Prevalence, predisposing factors, and clinical implications

Stoevesandt

Hosp

Kerstan

et al. 2018

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…It has been proposed that IgG prevents basophil activation by either intercepting antigen before it can cross‐link surface‐bound IgE or by binding to inhibitory receptors on mast cells triggering an inhibitory rather than activating signal . Other forms of immunotherapy including subcutaneous immunotherapy for bee venom and grass pollen induce an increase in IgG4 that intercepts antigen, preventing it from binding to cells. A previous study showed that peanut OIT‐induced IgG acts through the IgG receptor, FcγRII on basophils to inhibit their activation .…”

Section: Discussionmentioning

confidence: 99%

Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness

Orgel

Burk

Smeekens

et al. 2018

Clin Experimental Allergy

View full text Add to dashboard Cite

Background: Oral and sublingual immunotherapies for peanut allergy have demonstrated efficacy in small clinical trials; however, mechanisms and biomarkers correlating with clinical outcomes remain elusive. Previous studies have demonstrated a role for IgG in post-OIT plasma in the suppression of IgE-mediated mast cell reactions. Objective: The aim of this study was to characterize the role that peanut oral and sublingual immunotherapy-induced plasma factors play in the inhibition of ex vivo basophil activation and whether inhibitory activity is associated with clinical outcomes. Methods: Plasma samples from subjects on placebo, peanut oral immunotherapy (OIT) or peanut sublingual immunotherapy (SLIT), and IgG-depleted plasma or the IgG fraction were incubated with sensitized basophils, and the inhibition of basophil activation following stimulation with peanut extract was measured. Basophil inhibition results were compared between the two routes of immunotherapy, time on treatment and clinical outcomes. Results: Plasma from subjects after 12 months of active peanut OIT, but not placebo, inhibits basophil activation ex vivo. Depletion of IgG abrogated the blocking effect of OIT plasma, while the IgG fraction substantially blocked basophil activation. Basophils are inhibited to a similar extent by undiluted OIT and SLIT plasma; however, diluted OIT plasma from the time of desensitization challenge inhibited basophils more than diluted SLIT plasma from time of desensitization challenge.Plasma from subjects who experienced sustained unresponsiveness following OIT inhibited basophils to a greater extent than plasma from subjects who were desensitized, but this was not true for SLIT. Conclusions and ClinicalRelevance: Peanut immunotherapy induces IgG-dependent functional changes in plasma that are associated with OIT but not SLIT clinical outcomes. Understanding the mechanisms of peanut OIT and SLIT may help derive informative biomarkers. K E Y W O R D S basophil activation, food allergy, IgG, immunoglobulin, immunotherapy, peanut allergy

show abstract

“…It was recently shown that an increase in the IgG/IgE ratio correlates with a reduction in the frequency of specific IgE and skin reactions in patients who have undergone at least 3 years of VIT [197]. However, no validated tests are currently able to predict venom tolerance owing to variability in immunological parameters during VIT [198].…”

Section: High Tryptase Valuesmentioning

confidence: 99%

Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice

Bilò

Pravettoni

Bignardi

et al. 2019

J Investig Allergol Clin Immunol

115

View full text Add to dashboard Cite

Hymenoptera venom allergy is an epidemiologically underestimated condition representing an important cause of morbidity worldwide. Preventing future allergic reactions in patients who have developed a systemic reaction is based on the correct management of emergency followed by a correct diagnosis, prescription of adrenaline autoinjectors and, where indicated, specific venom immunotherapy (VIT). Some epidemiological studies highlight the poor knowledge of this disease and the frequent inadequacy of its management. Moreover, they emphasize the importance of such a life-saving treatment as specific immunotherapy. The availability of high quality Hymenoptera venom extracts for diagnostic and therapeutic use has dramatically improved the prognosis and the quality of life of allergic patients. The subcutaneous VIT represents the most effective form of immunotherapy with allergen presently available, with a carry-over effect lasting up to several years after its interruption. This report on the management of children and adults allergic to Hymenoptera venom was drawn up by a panel of Italian experts. The main objective of this consensus is to review the scientific evidences related to diagnosis, therapy and management of patients allergic to Hymenoptera venom and is aimed to improve the knowledge about this disease and promote good clinical practices. Practical suggestions for a correct diagnosis, prescription of emergency therapy and immunotherapy, as well as strategies for taking care of patients´ management are included.

show abstract

Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects

Cited by 32 publications

References 42 publications

Sensitization to Hymenoptera venom marker allergens: Prevalence, predisposing factors, and clinical implications

Sensitization to Hymenoptera venom marker allergens: Prevalence, predisposing factors, and clinical implications

Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness

Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice

Contact Info

Product

Resources

About